Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience

In the present study, the dosage and duration of rasburicase administration were retrospectively evaluated for the ability to control the serum uric acid (S-UA) level in 13 patients diagnosed with hematological malignancies and tumor lysis syndrome (TLS), or those at risk of developing TLS, at the U...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Lett
Egile Nagusiak: TAKAI, MIHOKO, YAMAUCHI, TAKAHIRO, MATSUDA, YASUFUMI, TAI, KATSUNORI, IKEGAYA, SATOSHI, KISHI, SHINJI, URASAKI, YOSHIMASA, YOSHIDA, AKIRA, IWASAKI, HIROMICHI, UEDA, TAKANORI
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2015
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467316/
https://ncbi.nlm.nih.gov/pubmed/26137024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.3009
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak